Hemosol to Host Annual and Special Meeting of Shareholders June 7, 2005
2005年5月31日 - 9:30PM
PRニュース・ワイアー (英語)
Hemosol to Host Annual and Special Meeting of Shareholders June 7,
2005 TORONTO, May 31 /PRNewswire-FirstCall/ -- Hemosol Inc.
(NASDAQ:HMSLNASDAQ:TSX: HML) today announced that the Company will
hold its Annual and Special Meeting of Shareholders at the TSX
Broadcast Centre, Gallery Room, 130 King Street West, Toronto,
Ontario, beginning at 10:00 am (EST) on June 7th, 2005. An
information circular was mailed to shareholders on May 17, 2005
describing the formal business to be dealt with at the meeting.
Subsequent to that mailing, Hemosol's Board has approved the
addition of Dr. Paul Walker to the slate of nominees to stand for
election as Directors of the corporation. Dr. Walker is the
President & CEO, as well as a Director of Spectral Diagnostics
Inc. Prior to accepting this corporate position, he was Chief
Operating Officer of the Toronto General Hospital. His medical
career included being Surgeon-in-Chief of the University Hospital
Network and Professor of Medicine and Laboratory Medicine at the
University of Toronto. He received his M.D. from the University of
Western Ontario, his PhD from the Salgrenska University of Goteborg
Sweden, and is the author of more than 100 scientific publications.
Dr. Walker is a also a graduate of the Advanced Management Program
from Harvard School of Business. Following the conclusion of the
formal business portion of the meeting, Lee Hartwell, Hemosol's
President & CEO, along with other members of the senior
management team, will provide a presentation covering the Company's
accomplishments in 2004 and goals and objectives for 2005. An audio
version of the meeting will be available on the Internet. To access
the live webcast please visit http://www.hemosol.com/. The
broadcast will be archived for up to 12 months. To listen to the
presentation you will need a standard web browser equipped with
Windows media player. About Hemosol Hemosol is a biopharmaceutical
company focused on the development and manufacturing of biologics,
particularly blood-related proteins. Hemosol has a broad range of
novel therapeutic products in development, including oxygen
therapeutics and protein-based therapeutics to treat certain
infectious diseases, cancers and anemia. For more information visit
Hemosol's website at http://www.hemosol.com/. The Common Shares are
listed on the NASDAQ Stock Market under the trading symbol "HMSL"
and on the TSX under the trading symbol "HML". Certain statements
concerning Hemosol's future prospects are "forward- looking
statements" within the meaning of the United States Private
Securities Litigation Reform Act of 1995 and other applicable
securities legislation. There can be no assurances that future
results will be achieved, and actual results could differ
materially from forecasts and estimates. Important factors that
could cause actual results to differ materially from forecasts and
estimates include, but are not limited to: Hemosol's ability to
successfully implement the Cascade technology and commercialize
products derived there from; Hemosol's ability to obtain additional
financing which is critical to the implementation of the Cascade
technology and to Hemosol's continued viability as a going concern;
Hemosol's ability to obtain regulatory approvals for its products;
Hemosol's ability to successfully complete clinical trials for its
products; Hemosol's ability to enter into satisfactory arrangements
for the supply of materials used in its manufacturing operations
and the sale of resulting products to customers; technical,
manufacturing or distribution issues; the competitive environment
for Hemosol's products and services; the degree of market
penetration of Hemosol's products; Hemosol's ability to attract and
retain clients for its bio-manufacturing services; the risk that
Hemosol may not become profitable; and other factors set forth in
filings with Canadian securities regulatory authorities and the
U.S. Securities and Exchange Commission. These risks and
uncertainties, as well as others, are discussed in greater detail
in the filings of Hemosol with Canadian securities regulatory
authorities and the U.S. Securities and Exchange Commission.
Hemosol makes no commitment to revise or update any forward-looking
statements in order to reflect events or circumstances after the
date any such statement is made. DATASOURCE: Hemosol Corp. CONTACT:
Jason Hogan, Investor & Media Relations, (416) 361-1331, (800)
789-3419, (416) 815-0080 fax, , http://www.hemosol.com/; Archived
images on this organization are searchable through CNW Photo
Archive website at http://photos.newswire.ca/. Images are free to
accredited members of the media. To request a free copy of this
organization's annual report, please go to http://www.newswire.ca/
and click on reports@cnw.
Copyright
Hemosol (NASDAQ:HMSL)
過去 株価チャート
から 4 2024 まで 5 2024
Hemosol (NASDAQ:HMSL)
過去 株価チャート
から 5 2023 まで 5 2024
Real-Time news about Hemosol (MM) (ナスダック市場): 0 recent articles
その他のHemosol - Common Shares (MM)ニュース記事